140 related articles for article (PubMed ID: 12052579)
1. Switching to amisulpride due to hepatic complications.
Yagdiran O; Haasen C; Nika E; Krausz M; Naber D
Eur Psychiatry; 2002 May; 17(3):170-1. PubMed ID: 12052579
[No Abstract] [Full Text] [Related]
2. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Freeman HL
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S11-7. PubMed ID: 9218163
[TBL] [Abstract][Full Text] [Related]
3. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
4. Clinical advantages of amisulpride in the treatment of acute schizophrenia.
Burns T; Bale R
J Int Med Res; 2001; 29(6):451-66. PubMed ID: 11803729
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of amisulpride in short- and long-term use.
Rein W; Coulouvrat C; Dondey-Nouvel L
Acta Psychiatr Scand Suppl; 2000; 400():23-7. PubMed ID: 10823308
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Colonna L; Saleem P; Dondey-Nouvel L; Rein W
Int Clin Psychopharmacol; 2000 Jan; 15(1):13-22. PubMed ID: 10836281
[TBL] [Abstract][Full Text] [Related]
7. Switching to amisulpride monotherapy for treatment-resistant schizophrenia.
Kontaxakis VP; Havaki-Kontaxaki BJ; Ferentinos PP; Paplos KG; Soldatos CR
Eur Psychiatry; 2006 Apr; 21(3):214-7. PubMed ID: 16531015
[TBL] [Abstract][Full Text] [Related]
8. Focus on amisulpride.
Green B
Curr Med Res Opin; 2002; 18(3):113-7. PubMed ID: 12094819
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on amisulpride in schizophrenia.
Curran MP; Perry CM
CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
[TBL] [Abstract][Full Text] [Related]
10. Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia.
Liang Y; Su YA; Zhao ZG; Gao N; Huang JZ; Tang MQ; Li KQ; Yang FD; Yu X; Si TM
J Clin Psychopharmacol; 2015 Oct; 35(5):583-6. PubMed ID: 26270200
[TBL] [Abstract][Full Text] [Related]
11. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.
Möller HJ; Boyer P; Fleurot O; Rein W
Psychopharmacology (Berl); 1997 Aug; 132(4):396-401. PubMed ID: 9298518
[TBL] [Abstract][Full Text] [Related]
12. Treatment of positive and negative symptoms: pharmacologic approaches.
Boyer P; Lecrubier Y; Puech AJ
Mod Probl Pharmacopsychiatry; 1990; 24():152-74. PubMed ID: 1970852
[No Abstract] [Full Text] [Related]
13. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Peuskens J; Möller HJ; Puech A
Eur Neuropsychopharmacol; 2002 Aug; 12(4):305-10. PubMed ID: 12126869
[TBL] [Abstract][Full Text] [Related]
14. Amisulpride and cardiomyopathy.
Brakoulias V; Bannan E; Cohen P; Geary G
Aust N Z J Psychiatry; 2005 Aug; 39(8):738. PubMed ID: 16050932
[No Abstract] [Full Text] [Related]
15. Amisulpride in schizophrenia.
Reid S; Turner J
Br J Psychiatry; 1998 May; 172():450. PubMed ID: 9747415
[No Abstract] [Full Text] [Related]
16. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.
Puech A; Fleurot O; Rein W
Acta Psychiatr Scand; 1998 Jul; 98(1):65-72. PubMed ID: 9696517
[TBL] [Abstract][Full Text] [Related]
17. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.
Speller JC; Barnes TR; Curson DA; Pantelis C; Alberts JL
Br J Psychiatry; 1997 Dec; 171():564-8. PubMed ID: 9519098
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
[TBL] [Abstract][Full Text] [Related]
19. Pisa syndrome. Report of a case.
Amore M; Cerisoli M; Campanile S; Campanile A
Ital J Neurol Sci; 1988 Jun; 9(3):273-4. PubMed ID: 2900225
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine response to antipsychotics: effects of drug type and gender.
Gründer G; Wetzel H; Schlösser R; Anghelescu I; Hillert A; Lange K; Hiemke C; Benkert O
Biol Psychiatry; 1999 Jan; 45(1):89-97. PubMed ID: 9894580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
